Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 results
from the RE-NOVATE(TM) trial demonstrated that oral dabigatran
etexilate once daily, administered for an average of 33 days, was
non-inferior to enoxaparin, also administered for an average of 33
days, in preventing venous thromboemb...
Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
... of investigational oral direct
thrombin inhibitor dabigatran
etexilate for the prevention of stroke and
Phase III clinical trial program investigating dabigatran
etexilate in more
than 34,000 patients for the pre...r
deaths (including deaths from bleeding).
The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
... Study results outline dabigatran
etexilate as potential thromboprophylaxis ther...sults
from the RE-NOVATE study, which investigated dabigatran
etexilate as a
potential therapy for patients unde... and 150mg)
of the oral direct thrombin inhibitor, dabigatran
for a median of 33 days, w...